Can we think of a TAT, that is a "tailored antiplatelet therapy"?

What can be seen from the case report by Verzelloni et al. has a double value, beyond the case itself. First of all, the use of platelet aggregation assessment tests, such as TEG-PM, allows clinicians to verify the exact timing between the suspension of thienopyridines and the possibility of surgery without further temporal delays and is also able to favor the evolution of ischemic problems or hemodynamic instability not easily treatable. It, therefore, allows clinicians to optimize the bleeding/thrombosis matching. Second, the use of point of care methodologies for the evaluation of platelet aggregation allows us to evaluate the adequacy of the antiaggregation, facilitating, where resistance or percentages of antiaggregation are lower than expected, modification of the therapeutic regimen.